 Kathryn Chatfield
Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Noonan Syndrome | 5 | 2022 | 17 | 2.470 |
Why?
| | Cardiolipins | 4 | 2025 | 83 | 1.490 |
Why?
| | Cardiomyopathies | 7 | 2025 | 336 | 1.440 |
Why?
| | Barth Syndrome | 2 | 2021 | 8 | 0.940 |
Why?
| | Heart Transplantation | 3 | 2019 | 711 | 0.900 |
Why?
| | Electron Transport Complex I | 2 | 2021 | 38 | 0.880 |
Why?
| | Myocardium | 6 | 2025 | 968 | 0.830 |
Why?
| | Williams Syndrome | 2 | 2021 | 13 | 0.790 |
Why?
| | Mitochondria, Heart | 3 | 2020 | 93 | 0.760 |
Why?
| | Pulmonary Valve Stenosis | 1 | 2021 | 19 | 0.720 |
Why?
| | Lipid Metabolism, Inborn Errors | 2 | 2025 | 19 | 0.710 |
Why?
| | Fatty Acids | 3 | 2025 | 417 | 0.700 |
Why?
| | General Practice | 1 | 2019 | 26 | 0.640 |
Why?
| | Cardiomyopathy, Hypertrophic | 4 | 2023 | 132 | 0.640 |
Why?
| | Alagille Syndrome | 1 | 2018 | 33 | 0.600 |
Why?
| | Ductus Arteriosus | 1 | 2018 | 71 | 0.600 |
Why?
| | DNA, Mitochondrial | 2 | 2020 | 190 | 0.580 |
Why?
| | Mutation | 9 | 2022 | 3696 | 0.530 |
Why?
| | Costello Syndrome | 3 | 2023 | 3 | 0.530 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2023 | 378 | 0.520 |
Why?
| | Turner Syndrome | 3 | 2022 | 52 | 0.510 |
Why?
| | Heart Defects, Congenital | 4 | 2022 | 750 | 0.500 |
Why?
| | 3-Hydroxyacyl CoA Dehydrogenases | 1 | 2015 | 9 | 0.470 |
Why?
| | Acetyl-CoA C-Acetyltransferase | 1 | 2015 | 9 | 0.470 |
Why?
| | ras Proteins | 4 | 2022 | 144 | 0.460 |
Why?
| | Heart Failure | 2 | 2019 | 2145 | 0.430 |
Why?
| | Heart Ventricles | 2 | 2020 | 767 | 0.430 |
Why?
| | Mitochondria | 2 | 2021 | 855 | 0.430 |
Why?
| | De Lange Syndrome | 1 | 2012 | 2 | 0.410 |
Why?
| | Infant | 12 | 2024 | 9001 | 0.390 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 3 | 2021 | 21 | 0.380 |
Why?
| | Pyrimidinones | 2 | 2023 | 103 | 0.380 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2042 | 0.360 |
Why?
| | Pyridones | 2 | 2023 | 158 | 0.360 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 45 | 0.350 |
Why?
| | Genetic Association Studies | 1 | 2012 | 361 | 0.350 |
Why?
| | Mydriasis | 2 | 2022 | 7 | 0.340 |
Why?
| | Child, Preschool | 8 | 2021 | 10487 | 0.330 |
Why?
| | Child | 16 | 2024 | 20805 | 0.330 |
Why?
| | Energy Metabolism | 1 | 2015 | 833 | 0.310 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1404 | 0.300 |
Why?
| | Chromosome Disorders | 2 | 2021 | 40 | 0.290 |
Why?
| | Acyltransferases | 3 | 2025 | 53 | 0.290 |
Why?
| | Humans | 37 | 2025 | 128499 | 0.290 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 1938 | 0.260 |
Why?
| | Phenotype | 4 | 2021 | 3051 | 0.260 |
Why?
| | Mitochondrial Trifunctional Protein | 1 | 2025 | 3 | 0.240 |
Why?
| | Mitochondrial Trifunctional Protein, alpha Subunit | 1 | 2025 | 3 | 0.240 |
Why?
| | Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase | 1 | 2025 | 3 | 0.240 |
Why?
| | Male | 19 | 2025 | 63045 | 0.240 |
Why?
| | Purpura | 1 | 2025 | 14 | 0.240 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 131 | 0.240 |
Why?
| | Female | 21 | 2024 | 68268 | 0.240 |
Why?
| | Heart Valve Diseases | 2 | 2024 | 151 | 0.240 |
Why?
| | Mitochondrial Membrane Transport Proteins | 2 | 2022 | 42 | 0.230 |
Why?
| | Bezafibrate | 1 | 2024 | 9 | 0.230 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 11 | 0.230 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 24 | 0.220 |
Why?
| | Niacinamide | 1 | 2024 | 73 | 0.220 |
Why?
| | Aortic Valve | 2 | 2024 | 348 | 0.210 |
Why?
| | Ectodermal Dysplasia | 1 | 2022 | 16 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 2019 | 45 | 0.200 |
Why?
| | Stress, Mechanical | 1 | 2024 | 463 | 0.200 |
Why?
| | Regional Blood Flow | 1 | 2024 | 458 | 0.200 |
Why?
| | Anesthetics | 1 | 2022 | 52 | 0.190 |
Why?
| | Hemodynamics | 2 | 2024 | 1077 | 0.190 |
Why?
| | Face | 2 | 2020 | 165 | 0.190 |
Why?
| | Gene Expression | 3 | 2018 | 1455 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2022 | 156 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 130 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 209 | 0.180 |
Why?
| | Segmental Duplications, Genomic | 1 | 2021 | 7 | 0.180 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 12 | 0.180 |
Why?
| | Infant, Newborn | 7 | 2018 | 5740 | 0.180 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 1003 | 0.180 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 259 | 0.180 |
Why?
| | Genetic Testing | 2 | 2021 | 428 | 0.180 |
Why?
| | Coenzyme A | 1 | 2020 | 8 | 0.180 |
Why?
| | Aorta | 2 | 2024 | 408 | 0.170 |
Why?
| | Urinary Bladder | 1 | 2022 | 175 | 0.170 |
Why?
| | Craniofacial Abnormalities | 1 | 2021 | 63 | 0.170 |
Why?
| | Biological Products | 1 | 2023 | 199 | 0.170 |
Why?
| | Echocardiography | 2 | 2024 | 624 | 0.170 |
Why?
| | Actins | 2 | 2022 | 403 | 0.170 |
Why?
| | Liver Diseases | 1 | 2022 | 287 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2021 | 149 | 0.160 |
Why?
| | Genes, ras | 1 | 2019 | 97 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 258 | 0.160 |
Why?
| | Electron Transport | 2 | 2020 | 112 | 0.160 |
Why?
| | Galactosyltransferases | 1 | 2018 | 11 | 0.150 |
Why?
| | Nitrogenous Group Transferases | 1 | 2018 | 2 | 0.150 |
Why?
| | Calcium | 2 | 2022 | 1183 | 0.150 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2018 | 15 | 0.150 |
Why?
| | Tachycardia, Ectopic Atrial | 1 | 2018 | 4 | 0.150 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2018 | 16 | 0.150 |
Why?
| | Marfan Syndrome | 1 | 2018 | 40 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 345 | 0.150 |
Why?
| | Postoperative Period | 1 | 2019 | 324 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 222 | 0.150 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 11 | 0.150 |
Why?
| | Mitochondrial Diseases | 1 | 2018 | 90 | 0.140 |
Why?
| | Constriction, Pathologic | 1 | 2018 | 228 | 0.140 |
Why?
| | Ventricular Remodeling | 1 | 2020 | 255 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.140 |
Why?
| | Protein Subunits | 1 | 2018 | 230 | 0.140 |
Why?
| | Seizures | 1 | 2021 | 400 | 0.140 |
Why?
| | Adolescent | 7 | 2024 | 20304 | 0.140 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2018 | 49 | 0.140 |
Why?
| | Infant Nutrition Disorders | 1 | 2017 | 11 | 0.140 |
Why?
| | NADH Dehydrogenase | 1 | 2017 | 18 | 0.140 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 190 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2021 | 3339 | 0.130 |
Why?
| | Myocytes, Cardiac | 1 | 2021 | 495 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 529 | 0.130 |
Why?
| | Retrospective Studies | 4 | 2024 | 14472 | 0.130 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2018 | 127 | 0.130 |
Why?
| | Emotions | 1 | 2021 | 535 | 0.130 |
Why?
| | Genetic Diseases, Inborn | 1 | 2016 | 38 | 0.130 |
Why?
| | Muscle, Smooth | 3 | 2022 | 152 | 0.130 |
Why?
| | Acyl Coenzyme A | 1 | 2015 | 30 | 0.120 |
Why?
| | Heart | 1 | 2019 | 637 | 0.120 |
Why?
| | Mental Retardation, X-Linked | 1 | 2015 | 13 | 0.120 |
Why?
| | Dyskinesias | 1 | 2015 | 19 | 0.120 |
Why?
| | Cell Respiration | 1 | 2015 | 98 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 311 | 0.110 |
Why?
| | Comorbidity | 1 | 2019 | 1541 | 0.110 |
Why?
| | Prevalence | 1 | 2021 | 2553 | 0.110 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2015 | 87 | 0.110 |
Why?
| | Muscles | 1 | 2015 | 322 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2269 | 0.110 |
Why?
| | Fibroblasts | 2 | 2018 | 937 | 0.110 |
Why?
| | Vascular Stiffness | 1 | 2018 | 463 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2021 | 1900 | 0.100 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2012 | 10 | 0.100 |
Why?
| | Age Factors | 2 | 2024 | 3122 | 0.100 |
Why?
| | Parents | 1 | 2021 | 1307 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2020 | 2679 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1689 | 0.100 |
Why?
| | Transcription Factors | 1 | 2020 | 1635 | 0.100 |
Why?
| | Genotype | 2 | 2019 | 1830 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 245 | 0.100 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 115 | 0.090 |
Why?
| | Registries | 1 | 2019 | 1883 | 0.090 |
Why?
| | Signal Transduction | 3 | 2023 | 4825 | 0.090 |
Why?
| | Syndrome | 2 | 2022 | 336 | 0.090 |
Why?
| | Genomics | 1 | 2014 | 715 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5371 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 581 | 0.080 |
Why?
| | Developmental Disabilities | 2 | 2021 | 259 | 0.070 |
Why?
| | Pregnancy | 2 | 2018 | 6373 | 0.070 |
Why?
| | Mice | 5 | 2025 | 16620 | 0.070 |
Why?
| | Proteins | 1 | 2012 | 936 | 0.070 |
Why?
| | Liver | 1 | 2015 | 1827 | 0.060 |
Why?
| | Mitochondrial Myopathies | 1 | 2025 | 8 | 0.060 |
Why?
| | Rhabdomyolysis | 1 | 2025 | 22 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2019 | 10162 | 0.060 |
Why?
| | Dilatation, Pathologic | 1 | 2024 | 60 | 0.060 |
Why?
| | Perfusion Imaging | 1 | 2024 | 56 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2719 | 0.060 |
Why?
| | Aortic Aneurysm | 1 | 2024 | 64 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 34 | 0.050 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2024 | 185 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 324 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 2024 | 404 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2022 | 29 | 0.050 |
Why?
| | Duodenum | 1 | 2022 | 71 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2024 | 253 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2741 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 97 | 0.050 |
Why?
| | United States | 1 | 2019 | 13840 | 0.050 |
Why?
| | Nervous System Diseases | 1 | 2025 | 252 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 152 | 0.050 |
Why?
| | Animals | 5 | 2025 | 34647 | 0.050 |
Why?
| | Chromosome Breakpoints | 1 | 2021 | 6 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 281 | 0.050 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2021 | 30 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 74 | 0.040 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2021 | 56 | 0.040 |
Why?
| | Myofibrils | 1 | 2021 | 49 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2023 | 212 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 102 | 0.040 |
Why?
| | Sarcomeres | 1 | 2021 | 92 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 164 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 12349 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 469 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 279 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 583 | 0.040 |
Why?
| | Adult | 3 | 2018 | 35302 | 0.040 |
Why?
| | SOS1 Protein | 1 | 2018 | 2 | 0.040 |
Why?
| | LEOPARD Syndrome | 1 | 2018 | 2 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2020 | 310 | 0.040 |
Why?
| | Enzyme Assays | 1 | 2018 | 25 | 0.040 |
Why?
| | Lentivirus | 1 | 2018 | 52 | 0.040 |
Why?
| | Digoxin | 1 | 2018 | 27 | 0.040 |
Why?
| | Amiodarone | 1 | 2018 | 24 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2024 | 1031 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 428 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 138 | 0.040 |
Why?
| | Propranolol | 1 | 2018 | 50 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2069 | 0.040 |
Why?
| | Lactoferrin | 1 | 1998 | 28 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2018 | 130 | 0.040 |
Why?
| | Proteomics | 1 | 2024 | 1018 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 186 | 0.040 |
Why?
| | Pedigree | 1 | 2018 | 485 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2019 | 260 | 0.030 |
Why?
| | Medical Records | 1 | 2018 | 170 | 0.030 |
Why?
| | Milk | 1 | 1998 | 119 | 0.030 |
Why?
| | Mammary Glands, Animal | 1 | 1998 | 124 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 468 | 0.030 |
Why?
| | Capital Financing | 1 | 2016 | 7 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2018 | 398 | 0.030 |
Why?
| | Arginine | 1 | 2018 | 260 | 0.030 |
Why?
| | Aorta, Thoracic | 1 | 2018 | 260 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 819 | 0.030 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 60 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 315 | 0.030 |
Why?
| | Enoyl-CoA Hydratase | 1 | 2015 | 8 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1119 | 0.030 |
Why?
| | Leigh Disease | 1 | 2015 | 19 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 584 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 487 | 0.030 |
Why?
| | Aged | 1 | 2014 | 21976 | 0.030 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2014 | 21 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 3947 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2014 | 33 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 2044 | 0.030 |
Why?
| | Patient Discharge | 1 | 2021 | 854 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 269 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 2018 | 524 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1562 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1698 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2765 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5045 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1484 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4017 | 0.030 |
Why?
| | Middle Aged | 1 | 2014 | 30923 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 3893 | 0.030 |
Why?
| | Mental Disorders | 1 | 2021 | 1007 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5402 | 0.020 |
Why?
| | Family | 1 | 2016 | 649 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1003 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2069 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2516 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3387 | 0.020 |
Why?
| | Lactation | 1 | 1998 | 170 | 0.010 |
Why?
| | Iron | 1 | 1998 | 282 | 0.010 |
Why?
|
|
Chatfield's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|